Clinical Trial News and Research

RSS

Cedars-Sinai experts to present research updates at International Stroke Conference

Stroke experts from Cedars-Sinai Medical Center will present research updates at the International Stroke Conference of the American Heart Association/American Stroke Association Feb. 1 through Feb. 3 in New Orleans.

3 Feb 2012

Version of 'Goldilocks' gene could determine future treatment for TB patients

'Goldilocks' gene could determine best treatment for TB patients Tuberculosis patients may receive treatments in the future according to what version they have of a single 'Goldilocks' gene, says an international research team from Oxford University, King's College London, Vietnam and the USA.

3 Feb 2012

Colchicine, another weapon against cancer

Finding a drug that targets only the diseased cells in our body and is otherwise harmless to healthy tissue is a goal for cancer researchers. It's driven the work of Professor Laurence Patterson, Director of the Institute of Cancer Therapeutics at the University of Bradford, and his team of researchers.

2 Feb 2012

Takeda, SPI announce that lubiprostone phase 3 trial on OBD meets primary endpoint

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.

2 Feb 2012

USF receives DOD grant for battlefield-related TBI research

The University of South Florida (USF) has received a $1.57 million U.S. Department of Defense grant to conduct translational research on traumatic brain injury and other battlefield related injuries and diseases.

2 Feb 2012

Genentech receives FDA approval for Vismodegib to treat skin cancer

A new skin cancer drug tested for the first time in the world five years ago at the Virginia G. Piper Cancer Center at Scottsdale Healthcare just received expedited approval by the U.S. Food and Drug Administration, a remarkable accomplishment in new drug development.

2 Feb 2012

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

Novartis announced today that following a priority review, the US Food and Drug Administration has approved an update to the Gleevec (imatinib mesylate) tablets label to recommend 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the risk of recurrence inclusion criteria of the pivotal trial.

1 Feb 2012

Affinium initiates AFN-1252 Phase 2 trial in acute bacterial skin & skin structure infections

Affinium Pharmaceuticals announced today dosing of the first patient in a multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections.

1 Feb 2012

New York hospital offers at-home method for tissue expansion for breast reconstruction surgery

NewYork-Presbyterian Hospital/Columbia University Medical Center is the first hospital in the New York metro area to offer breast cancer survivors an at-home method for tissue expansion in preparation for breast reconstruction surgery. Patients use a remote control to gradually create a space within their chest wall for a breast implant.

1 Feb 2012

OPN-305 may improve survival outcomes for kidney transplant patients

New research published online in the FASEB Journal details a new antibody, called "OPN-305" that may significantly improve survival outcomes for those receiving donated kidneys and other organs.

1 Feb 2012

Preliminary results from CINJ's Celebrex and Lipitor Phase II combination trial on prostrate cancer

Research from The Cancer Institute of New Jersey (CINJ) on the FDA-approved drugs Celebrex and Lipitor -- used respectively for arthritis pain and lowering cholesterol -- shows that these drugs are well tolerated in the treatment of recurrent prostate cancer.

1 Feb 2012

NIAID, Aeras partner for Phase II clinical trial of TB vaccine

Aeras announces today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), has joined as a partner for a Phase II proof-of-concept clinical trial of a tuberculosis vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell.

1 Feb 2012

Crizotinib can treat ROS1-driven tumors

A report from investigators at the Massachusetts General Hospital (MGH) Cancer Center has defined the role of a recently identified gene abnormality in a deadly form of lung cancer. Tumors driven by rearrangements in the ROS1 gene represent 1 to 2 percent of non-small-cell lung cancers (NSCLC), the leading cause of cancer death in the U.S.

1 Feb 2012

New combination clinical trial may improve outcome for cancer surgery patients

The week before and two weeks after surgery are a critical period for the long-term survival rate of cancer patients. Physiological and psychological stresses caused by the surgery itself can inhibit the body's immune responses, heightening vulnerability to tumor progression and spreading.

1 Feb 2012

IMUC president to present at Immunotherapeutics Partnering and Deal Making Conference

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Immunotherapeutics Partnering and Deal Making Conference, which will take place in San Diego, California on January 30-31, 2012.

31 Jan 2012

Breast cancer survivors use at-home method to prep their breasts for reconstruction

31 Jan 2012

Study compares needle fasciotomy and conventional surgery for Dupuytren's contractures

For disabling hand contractures caused by Dupuytren's disease, patients prefer a percutaneous needle fasciotomy procedure despite the higher contracture recurrence rate when compared to conventional surgery.

31 Jan 2012

Juventas' JVS-100 Phase I heart failure trial meets primary safety endpoint

Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease. The Company's lead product, JVS-100, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow.

31 Jan 2012

Research Down Syndrome enters second year of national running program

Research Down Syndrome (RDS), a nonprofit foundation that is among the leading sources for funding of Down syndrome related cognitive research, is entering the second year of its national running program, Race for the Extraordinary, to help increase public awareness and funding for Down syndrome research. The mission of RDS is the development of safe and effective therapies to address the intellectual difficulties associated with Down syndrome.

30 Jan 2012

Researchers develop new MRS technique to diagnose brain tumors

Researchers at UT Southwestern Medical Center have developed what they believe to be the first clinical application of a new imaging technique to diagnose brain tumors.

30 Jan 2012

Clinical Trial News and Research

Cedars-Sinai experts to present research updates at International Stroke Conference

Version of 'Goldilocks' gene could determine future treatment for TB patients

Colchicine, another weapon against cancer

Takeda, SPI announce that lubiprostone phase 3 trial on OBD meets primary endpoint

USF receives DOD grant for battlefield-related TBI research

Genentech receives FDA approval for Vismodegib to treat skin cancer

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

Affinium initiates AFN-1252 Phase 2 trial in acute bacterial skin & skin structure infections

New York hospital offers at-home method for tissue expansion for breast reconstruction surgery

OPN-305 may improve survival outcomes for kidney transplant patients

Preliminary results from CINJ's Celebrex and Lipitor Phase II combination trial on prostrate cancer

NIAID, Aeras partner for Phase II clinical trial of TB vaccine

Crizotinib can treat ROS1-driven tumors

New combination clinical trial may improve outcome for cancer surgery patients

IMUC president to present at Immunotherapeutics Partnering and Deal Making Conference

Breast cancer survivors use at-home method to prep their breasts for reconstruction

Study compares needle fasciotomy and conventional surgery for Dupuytren's contractures

Juventas' JVS-100 Phase I heart failure trial meets primary safety endpoint

Research Down Syndrome enters second year of national running program

Researchers develop new MRS technique to diagnose brain tumors

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer